Overview
- Pfizer has paid about $14.6 billion in dividends over the past six quarters, a pace that has significantly drained cash available for other priorities.
- The stock yields roughly 7%, far above the S&P 500 and peer pharmaceutical averages, which makes investors especially sensitive to any change in the payout.
- Trailing 12-month dividend payout exceeded 130% by end of Q1 2026 while the cash-based payout ratio was about 103%, showing that dividends have outpaced both earnings and cash generation.
- Key drugs that drive Pfizer’s revenue face patent expirations in 2027–2028 and the company currently has no confirmed large replacements after a public GLP-1 setback in 2025.
- Pfizer says the dividend is a priority and it has options to manage cash but a dividend cut remains a material risk that could reshape investor returns and force the company to shift spending toward R&D or balance-sheet moves.